<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Biosci.</journal-id>
<journal-title>Frontiers in Molecular Biosciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Biosci.</abbrev-journal-title>
<issn pub-type="epub">2296-889X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmolb.2020.598998</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Biosciences</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Non-catalytic-Region Mutations Conferring Transition of Class A &#x03B2;-Lactamases Into ESBLs</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Cao</surname> <given-names>Thinh-Phat</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1099363/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Yi</surname> <given-names>Hyojeong</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/544718/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Dhanasingh</surname> <given-names>Immanuel</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1070109/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ghosh</surname> <given-names>Suparna</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1070109/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Choi</surname> <given-names>Jin Myung</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1132337/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Lee</surname> <given-names>Kun Ho</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/674762/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ryu</surname> <given-names>Seol</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1132368/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kim</surname> <given-names>Heenam Stanley</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1132526/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lee</surname> <given-names>Sung Haeng</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1069089/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Cellular and Molecular Medicine, Chosun University School of Medicine</institution>, <addr-line>Gwangju</addr-line>, <country>South Korea</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Biomedical Sciences, Gwangju Alzheimer&#x2019;s Disease and Related Dementia Cohort Research Center, College of Natural Sciences and Public Health and Safety, Chosun University</institution>, <addr-line>Gwangju</addr-line>, <country>South Korea</country></aff>
<aff id="aff3"><sup>3</sup><institution>Division of Biosystems &#x0026; Biomedical Sciences, College of Health Sciences, Korea University</institution>, <addr-line>Seoul</addr-line>, <country>South Korea</country></aff>
<aff id="aff4"><sup>4</sup><institution>Aging Neuroscience Research Group, Korea Brain Research Institute</institution>, <addr-line>Daegu</addr-line>, <country>South Korea</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Chemistry, Chosun University</institution>, <addr-line>Gwangju</addr-line>, <country>South Korea</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Ki Duk Park, Brain Science Institute, Korea Institute of Science and Technology, South Korea</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Kyeong Kyu Kim, Sungkyunkwan University, South Korea; Sung-Kun (Sean) Kim, Northeastern State University, United States</p></fn>
<corresp id="c001">&#x002A;Correspondence: Heenam Stanley Kim, <email>hstanleykim@korea.ac.kr</email></corresp>
<corresp id="c002">Sung Haeng Lee, <email>sunglee@chosun.ac.kr</email></corresp>
<fn fn-type="other" id="fn002"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p></fn>
<fn fn-type="other" id="fn004"><p>This article was submitted to Protein Chemistry and Enzymology, a section of the journal Frontiers in Molecular Biosciences</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>11</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>7</volume>
<elocation-id>598998</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>08</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>10</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2020 Cao, Yi, Dhanasingh, Ghosh, Choi, Lee, Ryu, Kim and Lee.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Cao, Yi, Dhanasingh, Ghosh, Choi, Lee, Ryu, Kim and Lee</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Despite class A ESBLs carrying substitutions outside catalytic regions, such as Cys69Tyr or Asn136Asp, have emerged as new clinical threats, the molecular mechanisms underlying their acquired antibiotics-hydrolytic activity remains unclear. We discovered that this non-catalytic-region (NCR) mutations induce significant dislocation of &#x03B2;3-&#x03B2;4 strands, conformational changes in critical residues associated with ligand binding to the lid domain, dynamic fluctuation of &#x03A9;-loop and &#x03B2;3-&#x03B2;4 elements. Such structural changes increase catalytic regions&#x2019; flexibility, enlarge active site, and thereby accommodate third-generation cephalosporin antibiotics, ceftazidime (CAZ). Notably, the electrostatic property around the oxyanion hole of Cys69Tyr ESBL is significantly changed, resulting in possible additional stabilization of the acyl-enzyme intermediate. Interestingly, the NCR mutations are as effective for antibiotic resistance by altering the structure and dynamics in regions mediating substrate recognition and binding as single amino-acid substitutions in the catalytic region of the canonical ESBLs. We believe that our findings are crucial in developing successful therapeutic strategies against diverse class A ESBLs, including the new NCR-ESBLs.</p>
</abstract>
<kwd-group>
<kwd>extended-spectrum &#x03B2;-lactamase</kwd>
<kwd>non-catalytic-region ESBL</kwd>
<kwd>ceftazidime</kwd>
<kwd>antibiotic resistance</kwd>
<kwd>X-ray crystallography</kwd>
</kwd-group>
<contract-num rid="cn001">2016R1D1A1B03932717</contract-num>
<contract-num rid="cn001">2019R1F1A1049035</contract-num>
<contract-num rid="cn001">2018R1A2B2006456</contract-num>
<contract-sponsor id="cn001">National Research Foundation<named-content content-type="fundref-id">10.13039/501100001321</named-content></contract-sponsor>
<counts>
<fig-count count="5"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="54"/>
<page-count count="11"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Introduction</title>
<p>Extended-spectrum &#x03B2;-lactamases (ESBLs) are a serious threat to human health due to their enhanced hydrolytic activity against third-generation cephalosporins such as ceftazidime (CAZ), a representative first-line drug for bacterial diseases (<xref ref-type="bibr" rid="B12">Dance, 2014</xref>). In general, class A &#x03B2;-lactamases, regardless of subfamilies, share the similar overall structural architecture of their catalytic region (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S1</xref>), which can be separated into two major compartments: the conserved catalytic ensemble and the variable recognition ensemble. The conserved catalytic ensemble involving the hydrolysis of substrate consists of the reactive Ser70 which attacks the &#x03B2;-lactam amide bond; two general bases Lys73 and Glu166 which electrostatically activate the nucleophilic Ser70; the typical oxyanion hole formed by N atoms of Ser70 and Thr237 stabilizing the negative transient acyl-intermediate; the catalytic (or hydrolytic) water coordinated to Glu166 and Asn170, which disrupts the acyl-bond (<xref ref-type="bibr" rid="B36">Page, 2008</xref>; <xref ref-type="bibr" rid="B15">Drawz and Bonomo, 2010</xref>). On the other hand, the recognition ensemble, consisting of three critical segments including &#x03A9;-loop (160&#x2013;180 in the Ambler system) (<xref ref-type="bibr" rid="B49">Sirot et al., 1997</xref>; <xref ref-type="bibr" rid="B9">Celenza et al., 2008</xref>; <xref ref-type="bibr" rid="B13">Dobson et al., 2012</xref>; <xref ref-type="bibr" rid="B29">Levitt et al., 2012</xref>), lid (92&#x2013;118) (<xref ref-type="bibr" rid="B14">Doucet et al., 2004</xref>; <xref ref-type="bibr" rid="B7">Bethel et al., 2006</xref>), and strands &#x03B2;3-&#x03B2;4 (230&#x2013;251) (<xref ref-type="bibr" rid="B16">Du Bois et al., 1995</xref>; <xref ref-type="bibr" rid="B19">Giakkoupi et al., 2001</xref>; <xref ref-type="bibr" rid="B48">Shimizu-Ibuka et al., 2011</xref>; <xref ref-type="bibr" rid="B45">Ruggiero et al., 2017</xref>), is mostly responsible for the adaptability of class A &#x03B2;-lactamases toward different types of antibiotics (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S1</xref>). Upon the innovation of drugs, the residues in this ensemble are further varied to accommodate novel substrates, by which canonical catalytic-region ESBLs are to be produced. These three segments surrounding reactive Ser70 in the active site are known to mediate substrate recognition and hydrolysis directly, and these ESBLs originate in hot spot mutations by single amino acid substitutions in one of the segments of the wild-type &#x03B2;-lactamases<sup><xref ref-type="fn" rid="footnote1">1</xref></sup>. The mutations extend the substrate specificity of the enzyme by increasing the flexibility of the &#x03A9;-loop (<xref ref-type="bibr" rid="B53">Wang et al., 2002b</xref>), the charged state of the lid (<xref ref-type="bibr" rid="B43">Petit et al., 1995</xref>), and the interaction of the &#x03B2;3-&#x03B2;4 strands with substrates (<xref ref-type="bibr" rid="B24">Huletsky et al., 1993</xref>; <xref ref-type="bibr" rid="B37">Palzkill, 2018</xref>), indicating that the functionality and substrate specificity of the class A &#x03B2;-lactamases largely depend on the subtle changes in the size of the binding cleft.</p>
<p>Compared with these canonical ESBLs, the non-catalytic-region ESBLs (NCR-ESBLs) carry single amino-acid substitutions outside of the catalytic segments and potentially hydrolyze CAZ (<xref ref-type="bibr" rid="B21">Gniadkowski, 2001</xref>), while conserving residues for substrate binding (recognition ensemble) and hydrolysis (catalytic ensemble) virtually intact (<xref ref-type="bibr" rid="B42">Perez et al., 2007</xref>). To date, only two NCR mutations have been identified at the residue 69 (<xref ref-type="bibr" rid="B10">Chaibi et al., 1998</xref>; <xref ref-type="bibr" rid="B46">Sam et al., 2009</xref>; <xref ref-type="bibr" rid="B13">Dobson et al., 2012</xref>) in several class A &#x03B2;-lactamases, including PenL and at 136 (according to the Ambler system) in PenL alone (<xref ref-type="bibr" rid="B13">Dobson et al., 2012</xref>), which seem unlikely to involve substrate binding and hydrolysis (<xref ref-type="fig" rid="F1">Figure 1A</xref>). The ESBLs carrying mutations on the position of 69 have been reported from several class A &#x03B2;-lactamases including PenI of <italic>Burkholderia pseudomallei</italic> (<xref ref-type="bibr" rid="B46">Sam et al., 2009</xref>), SHV (<xref ref-type="bibr" rid="B20">Giakkoupi et al., 1998</xref>; <xref ref-type="bibr" rid="B23">Helfand et al., 2002</xref>; Monica A. <xref ref-type="bibr" rid="B51">Totir et al., 2006</xref>) and TEM (Samy O. <xref ref-type="bibr" rid="B32">Meroueh et al., 2002</xref>; <xref ref-type="bibr" rid="B53">Wang et al., 2002b</xref>), wherein the substitutions of Cys69 into Tyr or Met69 into Val, Ile, Leu, Tyr, Phe, or Lys conferred resistance to large size CAZ. Although several structural and kinetics studies suggested that such substitutions on Met69 may disrupt, or perturb the oxyanion hole of the active site (<xref ref-type="bibr" rid="B23">Helfand et al., 2002</xref>; <xref ref-type="bibr" rid="B53">Wang et al., 2002b</xref>; Monica A. <xref ref-type="bibr" rid="B51">Totir et al., 2006</xref>), those studies were unable to address the effect of substitution from Cys69 into bulky Tyr or Phe in case of Pen-type &#x03B2;-lactamase in a molecular level. Another NCR-ESBL carrying a mutation on the position of 136(Asn136Asp) has been reported only in PenL, which displays higher MIC values of CAZ than PenL-WT for <italic>B. thailandensis</italic> (<xref ref-type="bibr" rid="B13">Dobson et al., 2012</xref>). PenL (previously called, PenA) from <italic>B. thailandensis</italic> is a class A &#x03B2;-lactamase, which has been extensively studied with regard to its transition into an extended-spectrum &#x03B2;-lactamase (ESBL). This enzyme can evolve <italic>via</italic> a simple nucleotide-substitution, deletion, or duplication mutation to an ESBL, which can hydrolyze third-generation cephalosporins, including ceftazidime. Asn136 locating on helix &#x03B1;4 likely stabilizes &#x03A9;-loop by forming hydrogen bonds with the backbone of Glu166 (<xref ref-type="bibr" rid="B54">Yi et al., 2016</xref>). Note that Glu166 is one of the critical catalytic residues on &#x03A9;-loop for substrate binding in many of class A &#x03B2;-lactamases (<xref ref-type="bibr" rid="B15">Drawz and Bonomo, 2010</xref>), thereby forming an energetically unfavorable non-proline <italic>cis</italic>-peptide Glu166 and Xaa167 (Thr167 in PenL, Xaa refer any amino acid on the position as Ambler system). Asn136 is thus crucial for the proper functional orientation of Glu166 proven by the loss of function by substitution of Asn to Ala in the position of 136 of TEM-1 (<xref ref-type="bibr" rid="B4">Banerjee et al., 1998</xref>). Therefore, the substitution of Asn136 into Asp in PenL likely disrupts the &#x03A9;-loop&#x2019;s stability, which may affect the substrate specificity of the newly emerged NCR-ESBL. The molecular mechanism of resistance against CAZ by 136 NCR mutation, however, has not been investigated.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>NCR-ESBL-associated mutations and their kinetic analysis against CAZ. <bold>(A)</bold> The overall structure of PenL-WT containing the positions of the NCR-ESBL related mutations (Cys69Tyr and Asn136Asp) with three essential segments (lid, &#x03A9;-loop, and &#x03B2;3-&#x03B2;4) and CAZ hydrolysis-associated residues (black dots). <bold>(B)</bold> Kinetics of CAZ hydrolysis. The rate of CAZ hydrolysis by the two PenL-NCR-ESBLs plateaued, indicating the lower <italic>K</italic><sub><italic>M</italic></sub> value, increased catalytic efficiency <italic>K</italic><sub><italic>cat</italic></sub>/<italic>K</italic><sub><italic>M</italic></sub> (increased by 3&#x2013;5-fold, respectively) and enhanced CAZ affinity. Data are averages of triplicate determination in three or four independent experiments from different preparations and presented with standard deviation. The lines are fits of the Michaelis-Menten equation to the data. <bold>(C)</bold> Chemical structure of ceftazidime (CAZ) and ceftazidime-like glycyl boronic acid (CBA). Negatively charged groups harboring oxyimino moiety are marked with red boxes, and asterisks indicate the acetamido hydroxyl groups (see <xref ref-type="supplementary-material" rid="VS1">Supplementary Movie S1</xref>).</p></caption>
<graphic xlink:href="fmolb-07-598998-g001.tif"/>
</fig>
<p>In this study, we investigated the detailed molecular mechanisms underlying the acquired activity of the two NCR-ESBLs (PenL-Cys69Tyr and PenL-Asn136Asp) from <italic>Burkholderia thailandensis</italic> against CAZ, which do not directly involve with substrate binding and hydrolysis (<xref ref-type="bibr" rid="B10">Chaibi et al., 1998</xref>; <xref ref-type="bibr" rid="B20">Giakkoupi et al., 1998</xref>; <xref ref-type="bibr" rid="B13">Dobson et al., 2012</xref>; <xref ref-type="fig" rid="F1">Figure 1A</xref>). Our results demonstrate that NCR associated mutations consequently induce the subtle rearrangements on three critical catalytic segments(ensemble) of the PenL, including distortion of the strands &#x03B2;3-&#x03B2;4 and alteration of the electrostatic potentials around the canonical oxyanion hole (Cys69Tyr), enhancement of flexibility of the &#x03A9;-loop and increased fluctuation of strands &#x03B2;3-&#x03B2;4 (Asn136Asp). As a result, the substrate-binding cleft of the enzymes is enlarged to accommodate large CAZ.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S2.SS1">
<title>Expression and Purification</title>
<p>Genes encoding for PenL-Cys69Tyr and PenL-Asn136Asp were isolated as described previously (<xref ref-type="bibr" rid="B13">Dobson et al., 2012</xref>) and sub-cloned into pET28a(+) expression vector. <italic>E. coli</italic> BL21(DE3)-competent cell strain was used to overexpress PenL-WT, PenL-Cys69Tyr, and PenL-Asn136Asp. Transformed cells were grown in Luria-Bertani (LB) media supplemented with 100 &#x03BC;g/mL of kanamycin at 37&#x00B0;C until the OD<sub>600</sub> reached &#x223C; 0.6 and induced by 0.5 mM of isopropyl-&#x03B2;-D thiogalactopyranoside (IPTG). After an additional 16 h of incubation at 18&#x00B0;C, cells were centrifuged at 5,000 &#x00D7; <italic>g</italic> and 4&#x00B0;C for 20 min. Cell pellets were resuspended in a buffer containing 50 mM Tris-HCl, pH 7.5, 500 mM NaCl and 10 mM imidazole, supplemented with 0.1 mM phenylmethane sulfonyl fluoride (PMSF), 1 mM dithiothreitol (DTT), and DNase I. The resuspension cocktails were disrupted by high-intensity sonication at 4&#x00B0;C, and the insoluble fractions were separated using high-speed centrifugation (20,000 &#x00D7; <italic>g</italic> at 4&#x00B0;C for 30 min). The soluble fractions, containing the desired proteins with N-terminal 6 &#x00D7; His-tag, were loaded onto Ni-agarose columns. Unbound proteins were washed out with excess buffer containing 50 mM Tris-HCl, pH 7.5, 500 mM NaCl, and 20 mM imidazole. PenLs were eluted using the above buffer containing 250 mM imidazole. To remove the N-terminal 6 &#x00D7; His-tag, the eluted fractions were pulled and dialyzed against the buffer containing 20 mM Tris-HCl, 150 mM NaCl, and 2 mM CaCl<sub>2</sub>, pH 7.5, followed by treatment with 10 U of human &#x03B1;-thrombin (HTI, United States) per 1 mg/mL protein. PenLs were further purified <italic>via</italic> size-exclusion chromatography using a HiLoad 16/60 Superdex 200 pg column (GE Healthcare, United States) saturated with buffer (20 mM Tris-HCl, pH 7.5, and 50 mM NaCl).</p>
</sec>
<sec id="S2.SS2">
<title>Crystallization and Structural Analysis</title>
<p>The purified PenL-Cys69Tyr and PenL-Asn136Asp were concentrated to 10 &#x03BC;g/&#x03BC;l using a 10,000 Da cut-off Vivaspin centrifugal concentrator (Sartorius). Crystallization was carried out using the hanging drop vapor diffusion method by mixing a 1.2 &#x03BC;l protein sample with a 1.2 &#x03BC;l reservoir solution. Initial screenings were set up using commercial crystallization kits obtained from Hampton (USA) and Rigaku (Japan). Crystals of PenL-Cys69Tyr were grown in a solution containing 200 mM sodium acetate trihydrate and 20% (w/v) polyethylene glycol 3,350 at 4&#x00B0;C. By contrast, crystals of PenL-Asn136Asp were grown in a solution consisting of 100 mM sodium acetate at pH 5.0, 200 mM sodium chloride, and 25% (w/v) polyethylene glycol 3,350 at 20&#x00B0;C. Crystals were transferred to the cryo-solutions comprising a growth solution supplemented with 15&#x2013;20% glycerol for 30 s, followed by flash-freezing <italic>via</italic> immersion in liquid nitrogen.</p>
<p>To determine the complex structure of PenL-Cys69Tyr and PenL-Asn136Asp with ceftazidime-like glycylboronate (CBA), the cryo-solutions were supplemented with 2 mM CBA, followed by soaking crystals overnight at 4&#x00B0;C before flash-freezing. All the crystals were diffracted at a maximum of &#x223C;1.3 &#x00C5; resolution. X-ray diffraction and data collection were performed at Pohang Light Source (PLS) beamline 5C (Pohang, South Korea) using the ADSC Q315r CCD detector. Collected data were indexed, integrated, and scaled using HKL2000 (HKL Research Inc.). The structure of the two PenL variants was determined <italic>via</italic> molecular replacement using MolRep (<xref ref-type="bibr" rid="B1">Abergel, 2013</xref>) and the structure of PenL-WT (PDB code 5GL9) (<xref ref-type="bibr" rid="B54">Yi et al., 2016</xref>) as a reference model. The refinement was carried out with Refmac5 (<xref ref-type="bibr" rid="B33">Murshudov et al., 1997</xref>) and phenix.refine (<xref ref-type="bibr" rid="B3">Afonine et al., 2012</xref>; <xref ref-type="bibr" rid="B17">Echols et al., 2014</xref>). The coordinates and restraints of CBA were generated by eLBOW, and manually fitted to m<italic>Fo</italic>-<italic>Fc</italic> map employing Coot (<xref ref-type="bibr" rid="B18">Emsley and Cowtan, 2004</xref>). Details of data diffraction and structural refinement are shown in <xref ref-type="supplementary-material" rid="TS1">Supplementary Table S1</xref>.</p>
</sec>
<sec id="S2.SS3">
<title>Determination of Kinetic Parameters</title>
<p>Because of its poor spectroscopic property, ceftazidime (CAZ) can only be measured at a maximum of &#x223C;100 &#x03BC;M. Therefore, appropriate amounts of purified enzymes were mixed with various CAZ concentrations ranging from 5 to 100 &#x03BC;M in a reaction buffer comprising 50 mM potassium phosphate at pH 7.0 supplemented with 20 &#x03BC;g/mL of bovine serum albumin. The absorbance at 260 nm was immediately monitored at 25&#x00B0;C using a cuvette holder temperature controller. The initial velocity of PenL-WT was measured during the first 10 s using a standard procedure, and the velocities (<italic>v</italic>) were fitted to the Michaelis-Menten equation (<xref ref-type="supplementary-material" rid="TS1">Supplementary Information</xref>). The first-order persistence of reaction by PenL-WT prevented the calculation of <italic>K</italic><sub><italic>M</italic></sub> and <italic>k</italic><sub><italic>cat</italic></sub> within the experimental setup range; however, the catalytic efficiency can be estimated by reciprocal plotting, in which the slope of the regression curve is <italic>k</italic><sub><italic>cat</italic></sub>/<italic>K</italic><sub><italic>M</italic></sub>. Data fittings were carried out using in-house Python scripts with the power of SciPy (<xref ref-type="bibr" rid="B34">Oliphant, 2007</xref>) library for parameter estimation, and Matplotlib (<xref ref-type="bibr" rid="B25">Hunter, 2007</xref>) module for data visualization.</p>
</sec>
<sec id="S2.SS4">
<title>Molecular Dynamics Simulation</title>
<p>PenL-WT, PenL-Cys69Tyr, and PenL-Asn136Asp were subjected to all-atom molecular dynamics (MD) simulations in explicit solvent using Gromacs 5.0.7 suite (<xref ref-type="bibr" rid="B28">Lemkul et al., 2015</xref>) and Gromos96-43a1 force field (<xref ref-type="bibr" rid="B44">Ramos et al., 2019</xref>). The coordinate of PenL-WT was obtained from the RCSB Protein Data Bank by fetching the ID 5GL9 (<xref ref-type="bibr" rid="B54">Yi et al., 2016</xref>). Molecules were solvated using the TIP3P water model and neutralized with a cubic boundary of 0.10 M of NaCl. Particle mesh Ewald method (<xref ref-type="bibr" rid="B2">Abraham and Gready, 2011</xref>) was used to determine the electrostatic interaction of systems, with real space and a <italic>van der</italic> Waals distance cut-off of 10 &#x00C5;. After energy minimization by 500-step in steepest descent calculation, systems were heated to 300 K and simulated for 50 <italic>ns</italic>. The MD trajectory analysis was performed directly in the Gromacs package, and the RMSD and radius of gyration plotted with 100 frame intervals (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S8</xref>).</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<sec id="S3.SS1">
<title>Biochemical Properties of CAZ Hydrolysis by PenL Wild-Type and NCR-ESBLs</title>
<p>To elucidate the mechanism associated with CAZ hydrolysis by the two PenL NCR-ESBLs (PenL-Cys69Tyr and PenL-Asn136Asp), we first determined their kinetic parameters (<xref ref-type="table" rid="T1">Table 1</xref>). The two PenL NCR-ESBLs and wild-type PenL (PenL-WT) hydrolyzed CAZ over time in which the CAZ decay was linearly related to time for 10 s (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S2</xref>). <xref ref-type="fig" rid="F1">Figure 1B</xref> illustrates the comparative kinetics of CAZ hydrolysis by the two ESBLs and WT of PenL. The kinetics of CAZ hydrolysis were similar between the two ESBLs, with <italic>V</italic><sub><italic>max</italic></sub> and <italic>K</italic><sub><italic>M</italic></sub> values of 156.4 nmol/min per mg and 22.3 &#x03BC;M, respectively, for PenL-Cys69Tyr, and 155.8 nmol/min per mg and 12.5 &#x03BC;M, respectively, for PenL-Asn136Asp. The mutant&#x2019;s <italic>K</italic><sub><italic>M</italic></sub> values are 30&#x2013;60 times lower than that of WT (<xref ref-type="table" rid="T1">Table 1</xref>), indicating that a stable acyl-enzyme complex may be formed after binding in the mutant ESBLs. Although the <italic>k</italic><sub><italic>cat</italic></sub> values of the two PenL-ESBLs were lower than that of PenL-WT, their catalytic efficiency (<italic>k</italic><sub><italic>cat</italic></sub>/K<sub><italic>M</italic></sub>) was enhanced 3&#x2013;5-fold compared with that of PenL-WT (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="fig" rid="F1">Figure 1B</xref>, and see <xref ref-type="supplementary-material" rid="TS1">Supplementary Information</xref>). Those biochemical results are likely to correspond to the higher MIC values of CAZ than PenL-WT for <italic>B. thailandensis</italic> (<xref ref-type="bibr" rid="B13">Dobson et al., 2012</xref>). Overall, the changes in kinetic property, primarily with the decreased <italic>K</italic><sub><italic>M</italic></sub>, in the two PenL ESBL variants indicate that the two single substitutions led to alternative substrate recognition for the enzyme. Interestingly, the single mutations at non-canonical regions are involved neither in substrate binding or catalysis.</p>
<table-wrap position="float" id="T1">
<label>TABLE 1</label>
<caption><p>Kinetic parameters of ceftazidime hydrolysis.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left">Variant</td>
<td valign="top" align="center"><italic>K</italic><sub><italic>M</italic></sub></td>
<td valign="top" align="center"><italic>V</italic><sub><italic>max</italic></sub></td>
<td valign="top" align="center"><italic>k</italic><sub><italic>cat</italic></sub></td>
<td valign="top" align="center"><italic>k</italic><sub><italic>cat</italic></sub>/<italic>K</italic><sub><italic>M</italic></sub></td>
</tr>
<tr>
<td/>
<td valign="top" align="center">(&#x03BC;M)</td>
<td valign="top" align="center">(nmol/min/mg)</td>
<td valign="top" align="center">(s<sup>&#x2013;1</sup>)</td>
<td valign="top" align="center">(nM<sup>&#x2013;1</sup> s<sup>&#x2013;1</sup>)</td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">PenL-WT&#x002A;</td>
<td valign="top" align="center">643.91.07&#x002A;</td>
<td valign="top" align="center">1657.0384.63&#x002A;</td>
<td valign="top" align="center">2.00.460&#x002A;</td>
<td valign="top" align="center">3.0&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">PenL-Cys69Tyr</td>
<td valign="top" align="center">22.30.98</td>
<td valign="top" align="center">156.42.51</td>
<td valign="top" align="center">0.20.003</td>
<td valign="top" align="center">8.4</td>
</tr>
<tr>
<td valign="top" align="left">PenL-Asn136Asp</td>
<td valign="top" align="center">12.50.54</td>
<td valign="top" align="center">155.81.67</td>
<td valign="top" align="center">0.20.002</td>
<td valign="top" align="center">14.9</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<attrib><italic><italic>Data are means &#x00B1; SD of triplicate determination in three or four independent experiments. &#x002A;Estimated from linear regression.</italic></italic></attrib>
</table-wrap-foot>
</table-wrap>
<p>Next, to examine whether the enhanced CAZ affinity and catalytic efficiency were related to changes in the conformation of PenL-Cys69Tyr and PenL-Asn136Asp, Circular dichroism (CD) spectroscopy was used for comparison with that of wild-type (<xref ref-type="supplementary-material" rid="TS1">Supplementary Information</xref>). The CD spectra of their respective apo-forms (PenL-Cys69Tyr-apo and PenL-Asn136Asp-apo) showed no significant differences compared with the PenL-WT (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S3A</xref>). However, the CD spectra of the two NCR-ESBLs in the presence of a non-hydrolyzable CAZ analog glycylboronate (CBA) slightly deviated from their apo-forms as well as the PenL-WT-apo form. The degrees of the CD spectral change of the mutants appeared similar to that of WT from CAZ presence. Moreover, the deviations in a spectral difference between the two ESBLs seemed even less than those with CBA, which might result from the rapid hydrolysis of CAZ accompanied by the slight conformational changes (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S3B</xref>). These observations suggested that the conformation of the two NCR-ESBLs was similar to that of PenL-WT; however, the NCR-ESBLs may recognize the substrate CAZ (or CBA) by marginally changing their conformation of the side chain of residues in the active site or recognition ensemble.</p>
</sec>
<sec id="S3.SS2">
<title>Crystal Structures of PenL-Cys69Tyr NCR-ESBLs</title>
<p>To further investigate the conformational changes based on substrate recognition, we delineated four crystal structures of the two PenL NCR-ESBLs: two involving the apo-form and the other two associated with the CBA-bound form (<xref ref-type="supplementary-material" rid="TS1">Supplementary Table S1</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S4</xref>). Consistent with CD spectra, PenL-Cys69Tyr-apo and PenL-Asn136Asp-apo were structurally similar to PenL-WT (PDB ID:5GL9) (<xref ref-type="bibr" rid="B54">Yi et al., 2016</xref>) with root-mean-square deviations (RMSDs) of 0.221 and 0.186 &#x00C5; at their C&#x03B1; atoms relative to the wild-type, respectively (<xref ref-type="fig" rid="F2">Figure 2A</xref>). In particular, the configurations of the conserved catalytic residues and the catalytic water (W4) associated with hydrolysis coincided with those of PenL-WT (<xref ref-type="fig" rid="F3">Figures 3B</xref>, <xref ref-type="fig" rid="F2">2B</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S5</xref>). These similarities suggest that the respective substitution does not structurally alter the active site involved in acylation/diacylation of the &#x03B2;-lactam backbone during hydrolysis (<xref ref-type="bibr" rid="B27">Lamotte-Brasseur et al., 1991</xref>; <xref ref-type="bibr" rid="B36">Page, 2008</xref>; <xref ref-type="bibr" rid="B8">Brown et al., 2009</xref>; <xref ref-type="bibr" rid="B15">Drawz and Bonomo, 2010</xref>; <xref ref-type="bibr" rid="B39">Papp-Wallace et al., 2013</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>Structure of NCR-ESBLs and Cys69Tyr mutation-induced &#x03B2;3-&#x03B2;4 changes. <bold>(A)</bold> Superposition of structures of the PenL NCR-ESBLs with PenL-WT. The structural similarity over the entire molecule is shown. Typically, the configuration of side chains for catalytic residues is well preserved among the proteins. <bold>(B)</bold> Comparison of active site between WT and Cys69Tyr variant. The catalytic residues from both proteins coordinate the catalytic waters (W4), which coincide in the active site. <bold>(C)</bold> Structural changes in &#x03B2;3-&#x03B2;4 of PenL-Cys69Tyr. Replacement of bulky Tyr at 69 increases the flexibility of &#x03C4;&#x03B7;&#x03B5;&#x03B2;3-&#x03B2;4 loop (&#x223C;7.4 &#x00C5; at Tyr241) by disassembly of &#x03B2;4. The change induces the dislocation of a loop between &#x03B2;5 and &#x03B1;8 (&#x223C;10.8 &#x00C5; at Arg270) and flip Arg275 on the &#x03B2;5-&#x03B1;8 loop toward the substrate-binding region, resulting in expansion of the active site and altered electronic properties of the oxyanion hole. <bold>(D)</bold> The active site structure of PenL-Cys69Tyr-CBA. Residues on b3 involved in the interaction with CBA, and Tyr105 also move upward for facilitating the entry of large substrate (see also <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S6A</xref>). Arg275 keeps its conformation projecting into the oxyanion hole, and Tyr241 moves back to that of WT to some extent.</p></caption>
<graphic xlink:href="fmolb-07-598998-g002.tif"/>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>Electrostatic potential changes in the catalytic cavity of PenL-Cys69Tyr. <bold>(A)</bold> Electrostatic property of the active site in PenL-WT. <bold>(B,C)</bold> Electrostatic distribution in the substrate-binding cleft of PenL-Cys69Tyr-apo and CBA-bound form (acylated). Residues such as Tyr69, Se70, Arg104, Glu166, Asn170, Arg275, and W4 catalytic water molecule are actively involved in substrate binding, acylation-deacylation step, and oxyanion hole formation (see <xref ref-type="supplementary-material" rid="VS2">Supplementary Movie S2</xref>).</p></caption>
<graphic xlink:href="fmolb-07-598998-g003.tif"/>
</fig>
<p>Interestingly, the PenL-Cys69Tyr-apo showed structural variation in the &#x03B2;3-&#x03B2;4 strands compared with PenL-WT-apo (<xref ref-type="fig" rid="F2">Figure 2C</xref>). Notably, the C-terminus of &#x03B2;3 and the N-terminus of &#x03B2;4 in PenL-Cys69Tyr-apo were disrupted in three (Thr237 to Asp240) and two (Thr243 to Gly244) residues, respectively. The disruption in the &#x03B2;-strands was apparently induced by the steric hindrance of bulky Tyr69 against the &#x03B2;3-&#x03B2;4 sheet, resulting in enhanced flexibility and dislocation of the loop by 7.4 &#x00C5; at Tyr241 (<xref ref-type="fig" rid="F2">Figure 2C</xref>). The increased flexibility of the &#x03B2;4 N-terminus in PenL-Cys69Tyr-apo induced a loss of hydrogen bonds with adjacent C-terminus of &#x03B2;5 and subsequently dislocated the &#x03B2;5-&#x03B1;8 loop away from the corresponding position of Pen-WT-apo by 10.8 &#x00C5; at Arg270 (<xref ref-type="fig" rid="F2">Figure 2C</xref> and <xref ref-type="supplementary-material" rid="VS1">Supplementary Movie S1</xref>). Since the &#x03B2;3-&#x03B2;4 segment is one of the recognition ensembles, these changes likely expand the active site of the enzyme to accommodate large substrates such as CAZ. The structure of PenL-Cys69Tyr-CBA shows that the residues ranging from Thr237 to Asp240 of &#x03B2;3 mediated substrate recognition, and the loop interacts with the aminothiazole ring and acetamido backbone, rather than the oxyimino group of CBA (<xref ref-type="fig" rid="F2">Figure 2D</xref>). These results suggest that the NCR mutation induced similar effects as in the known canonical ESBLs. For instance, the dislocation of the loop between &#x03B2;3-&#x03B2;4 strands in TEM-52 ESBL (Gly238Ser on &#x03B2;3) enlarged the active site to bind CAZ without further loop extension and with minimal dislocation (&#x223C;2.9 &#x00C5;) (<xref ref-type="bibr" rid="B40">Papp-Wallace et al., 2012</xref>). In addition to structural analysis, we calculated the electrostatic distribution on the surface of proteins (<xref ref-type="fig" rid="F3">Figure 3</xref>). Surprisingly, we found a significant change in electrostatic property from negative to positive in the active site of PenL-Cys69Tyr-apo, which has never been reported in ESBLs. Upon distortion of strands &#x03B2;3-&#x03B2;4, the helix &#x03B1;8 was extended by four residues (Ala272-Arg275) (<xref ref-type="fig" rid="F2">Figure 2C</xref> and <xref ref-type="supplementary-material" rid="VS1">Supplementary Movie S1</xref>). Accordingly, Arg275 rotated 180&#x00B0; to relocate closer to the Thr237 with a distance of &#x223C;6.7 &#x00C5; (between N atom of Arg275 and backbone N of Thr237) in the Arg220-Asp276-Thr237 cluster, which is critical for substrate binding and hydrolysis (<xref ref-type="bibr" rid="B38">Papp-Wallace et al., 2010</xref>, <xref ref-type="bibr" rid="B40">2012</xref>; <xref ref-type="fig" rid="F2">Figures 2C,D</xref>, <xref ref-type="fig" rid="F3">3C</xref>). The Thr237 residue in the cluster mainly contributed to the oxyanion hole, stabilizing the tetrahedral intermediate formed <italic>via</italic> nucleophilic attack by catalytic Ser70 (<xref ref-type="fig" rid="F2">Figures 2C</xref>, <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S5</xref>). Note that, based on the established mechanism of &#x03B2;-lactam hydrolysis (<xref ref-type="bibr" rid="B15">Drawz and Bonomo, 2010</xref>; <xref ref-type="bibr" rid="B39">Papp-Wallace et al., 2013</xref>), the N atom of Ambler residue 237 (i.e., Thr237 in this case) participates in the formation of the oxyanion hole, stabilizing the tetrahedral intermediate of a substrate with class A &#x03B2;-lactamase. Besides the residue 237 in the cluster, Arg220, whose configuration was not changed between PenL-WT and PenL-Cys69Tyr, is directly in close contact with Thr237 (&#x223C;4.4 &#x00C5;) (<xref ref-type="fig" rid="F2">Figures 2C,D</xref>). Remarkably, the Arg275 in the Cys69Tyr mutant positions adjacent to Arg220 within &#x223C;3.6 &#x00C5;, which may strengthen the positive charge around the oxyanion hole (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S9C</xref>). Consequently, the accumulation of additional basic amino acid (i.e., Arg275) increased the positive electrostatic potential around the oxyanion hole (<xref ref-type="fig" rid="F3">Figure 3</xref> and <xref ref-type="supplementary-material" rid="VS2">Supplementary Movie S2</xref>). Notably, due to the presence of two negatively charged groups on CAZ (<xref ref-type="fig" rid="F1">Figure 1C</xref>), the increased net positive charge in the PenL-Cys69Tyr active site may enhance the binding affinity with CAZ, which is consistent with the kinetic data (<xref ref-type="table" rid="T1">Table 1</xref>). Taken together, the findings indicate that the Cys69Tyr mutation in class A &#x03B2;-lactamase affects the structural interaction between &#x03B2;3&#x2013;&#x03B2;4 strands and substrate by enlarging the substrate-binding cleft of the enzyme and altering electrostatic property around the oxyanion hole in the active site. These changes in the NCR-ESBL may result in enhanced recognition of large CAZ without affecting the conserved catalytic residues of class A &#x03B2;-lactamases located in the active site for hydrolysis.</p>
</sec>
<sec id="S3.SS3">
<title>Crystal Structure of PenL-Asn136Asp NCR-ESBL</title>
<p>Similar to Cys69, the residue Asn136 is positioned outside the essential catalytic segments and not involved in the catalysis of antibiotics. However, a novel ESBL variant carrying the substitution of Asn136Asp was found only in PenL (<xref ref-type="bibr" rid="B13">Dobson et al., 2012</xref>) and also exhibited an increase in CAZ hydrolysis activity (<xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="fig" rid="F1">Figure 1B</xref>). Asn136 is located proximally to active site cleft so that its side chain forms a hydrogen bond to the backbone of Glu166 on &#x03A9;-loop and stabilizes the energetically unfavorable non-proline <italic>cis</italic>-peptide (<xref ref-type="bibr" rid="B6">Berg et al., 2012</xref>) between Glu166-Thr167 (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Notice that Glu166 is a critical catalytic residue that involved in both the activation of the Ser70 and deacylation step in &#x03B2;-lactam hydrolysis (<xref ref-type="bibr" rid="B27">Lamotte-Brasseur et al., 1991</xref>; <xref ref-type="bibr" rid="B22">Guillaume et al., 1997</xref>; <xref ref-type="bibr" rid="B31">Meroueh et al., 2005</xref>; <xref ref-type="bibr" rid="B36">Page, 2008</xref>; <xref ref-type="bibr" rid="B15">Drawz and Bonomo, 2010</xref>; <xref ref-type="bibr" rid="B39">Papp-Wallace et al., 2013</xref>). Asn136 thus appears to be responsible for the proper orientation of Glu166 and &#x03A9;-loop. Evidently, the loss of the stabilization by Asn136 (i.e., by mutation Asn136Ala) resulted in the functional deficiency of a class A &#x03B2;-lactamase (<xref ref-type="bibr" rid="B5">Banerjee et al., 1997</xref>, <xref ref-type="bibr" rid="B4">1998</xref>). The replacement of Asn136 to aspartate abolishes a hydrogen bond formed with Glu166 in WT (<xref ref-type="fig" rid="F4">Figure 4A</xref>), which probably leads to an increase in &#x03A9;-loop flexibility. To our surprise, the structure of PenL-Asn136Asp demonstrates no significant difference in comparison with PenL-WT (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Nonetheless, PenL-Asn136Asp can accommodate the CBA into its active site wherein the conformation does not change substantially (<xref ref-type="fig" rid="F4">Figure 4C</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S6</xref>). Residue Arg275 also adopts the same configuration as that of the wild-type enzyme, implying no such alteration of electrostatic distribution around active site cleft, as seen in PenL-Cys69Tyr (<xref ref-type="fig" rid="F4">Figure 4B</xref>). However, the large-sized CAZ may bind to the active site with the help of the change in lid segment, although no such considerable distinction between PenL-Asn136Asp and PenL-WT, as well as between PenL-Asn136Asp-apo and PenL-Asn136Asp-CBA, is observed. Two residues, including Arg104 and Tyr105, in the lid of PenL-Asn136Asp-apo, appeared to move away from the active site than WT (<xref ref-type="fig" rid="F4">Figures 4B,C</xref>). In PenL-Asn136Asp-apo, residue Arg104 swung away by &#x223C;4.0 &#x00C5; from the corresponding position of WT, whereas Tyr105moved upward by &#x223C;1.3 &#x00C5;. Then, Arg104 returned toward the active site when the CBA bound. Instead, the Tyr105 moved further upward by another 2.0 &#x00C5; in the CBA bound form (<xref ref-type="fig" rid="F4">Figure 4</xref>, <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S7</xref>, and <xref ref-type="supplementary-material" rid="VS3">Supplementary Movie S3</xref>). These observations indicate that Asn136Asp mutation may affect the conformation of the lid segment to expand the size of the substrate-binding cleft and receive large size CAZ. Interestingly, the changes in the lid resemble that the effects of mutation on &#x03A9;-loop propagated into those residues to enlarge and accommodate CAZ (<xref ref-type="bibr" rid="B54">Yi et al., 2016</xref>). Therefore, the mutation at 136 may cause the instability of the &#x03A9;-loop.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p>Structure of Asn136Asp NCR-ESBL and changes on lid. <bold>(A)</bold> Superposition of structures of the PenL-Asn136Asp-apo with WT. The side chain configurations of catalytic residues are superimposed regardless of the mutation. <bold>(B)</bold> Conformational change on the lid segment. Asp104 and Tyr105 in apo-form were displaced from substrate-binding cleft compared to those in WT, resulting in the expansion of the active site&#x2019;s size. <bold>(C)</bold> Structure of PenL-Asn136Asp-CBA. The two residues, including Arg104 and Tyr105, underwent subsequent structural changes upon CBA binding. Moving Arg104 toward CBA (red arrow) and lifting Tyr105 upward further from the active site (red arrow) are likely to provide a large substrate like CAZ with adequate space. However, the &#x03B2;3-&#x03B2;4 and residues that underwent conformational changes in the Cys69Tyr variant remained unchanged (see <xref ref-type="supplementary-material" rid="VS3">Supplementary Movie S3</xref> and compare <xref ref-type="fig" rid="F2">Figure 2</xref>).</p></caption>
<graphic xlink:href="fmolb-07-598998-g004.tif"/>
</fig>
<p>An interesting question can then be raised here on how the relatively negative CAZ can be attracted to an electrostatically negative substrate-binding cleft of the PenL-Asn136Asp (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S6</xref>) like that of PenL-WT. Taken together with the CD spectra data and kinetic analysis, these observations indicate that the binding of CAZ into the binding site might be governed by latent factors other than the electrostatic attraction, which was not be revealed in the static crystal structure. We thereby suggest two hypotheses. First, the higher degree of freedom would be induced to the &#x03A9;-loop of PenL-Asn136Asp due to the loss of one hydrogen bond by the mutation that occurred outside the &#x03A9;-loop. Indeed, this effect resembles cases in other class A &#x03B2;-lactamase ESBLs where the stable network on &#x03A9;-loop <italic>per se</italic> was devastated by the substitutions at Ambler position Arg164 or Asp179 located on &#x03A9;-loop (<xref ref-type="bibr" rid="B35">Orencia et al., 2001</xref>; <xref ref-type="bibr" rid="B52">Wang et al., 2002a</xref>). In this case, the resulting enhanced flexible motion of &#x03A9;-loop may induce the transient enlargement of active site cleft and facilitate the accommodation of third-generation cephalosporins like CAZ or CTX. Second, the mutation Asn136Asp may create intrinsic dynamic conformers that would efficiently accommodate CAZ. The viewpoint of functional promiscuity in protein conformation has been suggested formerly (<xref ref-type="bibr" rid="B50">Tokuriki and Tawfik, 2009</xref>), whereby poorly packed or disordered conformation by an accumulation of single mutations in proteins evolves conformationally diverse structures to adapting novel substrates.</p>
</sec>
<sec id="S3.SS4">
<title>Dynamics in Catalytic Regions of NCR-ESBLs</title>
<p>For the reasons, the molecular dynamics (MD) simulation was therefore conducted to compare the dynamic property of PenL-Asn136Asp with PenL-WT and PenL-Cys69Tyr on the CAZ binding (<xref ref-type="fig" rid="F5">Figure 5</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S8</xref>). The MD simulation indicates that the overall structure of PenL-Asn136Asp was stable through a 50 ns trajectory and roughly similar to PenL-WT. However, RMSD at three critical segments of PenL-Asn136Asp, similar to PenL-Cys69Tyr, was higher than PenL-WT and appeared to fluctuate, especially at the lid region (<xref ref-type="fig" rid="F5">Figure 5</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure 8</xref>). Furthermore, the radius of gyration (Rgyr) plots also demonstrate a potential unfolding of two PenL-ESBLs, in contrast to the sustainable motion of PenL-WT (<xref ref-type="fig" rid="F5">Figure 5</xref>). These observations strongly suggest that PenL-Asn136Asp (and PenL-Cys69Tyr) has a higher tendency for disorder than PenL-WT, which is correlated with the higher adaptability toward CAZ in term of <italic>protein dynamism</italic> (<xref ref-type="bibr" rid="B50">Tokuriki and Tawfik, 2009</xref>). In the molecular view, two regions appeared to involve in the accommodation of the large-size antibiotics followed by the transient disorder. First, the MD results showed the serial propagation of the mutation effect from &#x03A9;-loop into the &#x03B2;3-&#x03B2;4 element. The conformations of primary residues, including Asn136, Glu166, reactive Ser170, and the three essential catalytic segments involved in binding, remained unchanged in PenL-WT through MD trajectory (<xref ref-type="fig" rid="F5">Figure 5A</xref>). By contrast, the mutant Asp136 side chain in PenL-Asn136Asp-apo shifted away from the Glu166 backbone of &#x03A9;-loop, leading to a large fluctuation of Glu166 (approximately 5.2 &#x00C5;) and Ser70 (<xref ref-type="fig" rid="F5">Figures 5B,C</xref>, <xref ref-type="supplementary-material" rid="TS1">Supplementary Figures S8B,C</xref> and <xref ref-type="supplementary-material" rid="VS4">Supplementary Movie S4</xref>). Surprisingly, the high degree of fluctuation involving the &#x03A9;-loop and Ser70 pushed the &#x03B2;3&#x2013;&#x03B2;4 loop away <italic>via</italic> steric hindrance with a concurrent breakdown of the hydrogen bond between Asn170 and Asp240, located on the &#x03A9;-loop and &#x03B2;3, respectively (<xref ref-type="fig" rid="F4">Figures 4B</xref>, <xref ref-type="fig" rid="F5">5C</xref> and <xref ref-type="supplementary-material" rid="VS4">Supplementary Movie S4</xref>). The changes in the regions, which are intensively involved in substrate recognition, may result in the momentary expansion of the active site space and the improvement of CAZ binding, likewise observed from PenL-Cys69Tyr and &#x03A9;-loop tandem repeat ESBL of PenL (<xref ref-type="bibr" rid="B54">Yi et al., 2016</xref>). Second, the Arg104 residue in PenL-Asn136Asp-apo penetrated the substrate-binding region compared with the Pen-WT, to facilitate the recognition and interaction with acetamido backbone of CBA through hydrogen bonding (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S6B</xref>). Interestingly, the conformation of Arg104 in PenL-Asn136Asp-CBA was similar to those of PenL-Cys69Tyr-apo and -CBA, but further away than PenL-Asn136Asp-apo, suggesting that the entry of Arg104 into the substrate-binding cleft stabilized the acyl-form of PenL-Cys69Tyr <italic>via</italic> interaction with W5 in CBA (<xref ref-type="fig" rid="F5">Figure 5C</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S6</xref>). The increased affinity of PenL-Asn136Asp to CAZ also supported this result compared with PenL-WT (<xref ref-type="table" rid="T1">Table 1</xref>). Besides, Tyr105 in PenL-Asn136Asp-CBA, a well-conserved residue for ligand interaction (<xref ref-type="bibr" rid="B39">Papp-Wallace et al., 2013</xref>), was dislocated further way than the PenL-WT and PenL-Asn136Asp-apo (<xref ref-type="fig" rid="F4">Figures 4C</xref>, <xref ref-type="fig" rid="F5">5C</xref>). Indeed, the side-chain conformation of two residues in PenL-Asn136Asp dislocated further away from the substrate-binding site in crystal structures with respect to those of PenL-Cys69-Tyr and WT (<xref ref-type="fig" rid="F4">Figure 4</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S7</xref>). Therefore, the changes involving the lid region may induce momentary expansion of the active site and improve CAZ binding in the PenL-Asn136Asp and PenL-Cys69Tyr as in the canonical ESBLs (<xref ref-type="bibr" rid="B41">Patel et al., 2017</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p>Dynamics of catalytic regions in PenL-WT and NCR-ESBLs. The dynamics of the representative residues are shown from initial to expanded state with arrows. <bold>(A)</bold> Dynamics of PenL-WT. Most of the residues are static during simulation except for Arg104 that fluctuates horizontally. <bold>(B)</bold> PenL-Cys69Try and <bold>(C)</bold> PenL-Asn136Asp during the 50 ns MD simulation. The dynamics of substrate binding residues and the major catalytic regions, including &#x03A9;-loop, &#x03B2;3-&#x03B2;4 strands, and lid in the NCR-ESBLs, enlarge the opening of the substrate-binding active site (see <xref ref-type="supplementary-material" rid="VS4">Supplementary Movie S4</xref>).</p></caption>
<graphic xlink:href="fmolb-07-598998-g005.tif"/>
</fig>
</sec>
</sec>
<sec id="S4">
<title>Discussion</title>
<p>We demonstrated that the effects of the two NCR mutations in ESBLs ultimately converged to the recognition ensemble that is one of the catalytic regions. The finding suggests a common evolutionary mechanism underlying the expansion of the substrate spectrum in &#x03B2;-lactamases, i.e., by widening the catalytic cleft for large-size antibiotics with high affinity <italic>via</italic> changes in local segments regardless of the location of mutations. Further, the electrostatic environment surrounding the oxyanion hole in PenL-Cys69Tyr can be modified by mutations enhancing substrate recognition. Although the Arg275 dislocation in PenL-Cys69Tyr accounts for the enhanced positive charge distribution around oxyanion hole, the Arg&#x2019;s substantial contribution to the charge transition is still in question due to the quite remote distance (&#x223C;6.7 &#x00C5;) from Thr237 on &#x03B2;3-&#x03B2;4 (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S9A</xref>) and the dynamic fluctuations (<xref ref-type="fig" rid="F5">Figure 5</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S8C</xref>). Of the MD simulation frames, several configurations regarding the Arg275 and Arg220 showed an augmented proximity to the active site with &#x223C;4.0 &#x00C5; and &#x223C;4.4 &#x00C5;, respectively (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figures S9B,C</xref>). Furthermore, the disrupted regions (loop) on &#x03B2;3-&#x03B2;4 and &#x03B2;5-&#x03B1;8 (<xref ref-type="fig" rid="F2">Figure 2C</xref>) by the Cys69Tyr mutation moves toward the active site as Arg275 approaches to Thr237, indicating the supply of N atoms nearer to the oxyanion hole (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S8C</xref>). Therefore, the above arrangement of the basic residues and atoms in PenL-Cys69Tyr may induce a strong positive charge in the region around its oxyanion hole, which subsequently attracts the negative moiety-containing substrate, CAZ. The typical oxyanion hole, which is comprised of N atoms of reactive Ser70 and Thr237, and water W6 (<xref ref-type="fig" rid="F2">Figure 2</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figures S5</xref>, <xref ref-type="supplementary-material" rid="TS1">S6</xref>), is responsible for sustaining the carbonyl group of &#x03B2;-lactam backbone once the &#x03B2;-lactam is attacked by nucleophilic Ser70. Likewise, the tetrahedral intermediate of the substrate in both CBA-bound complex structures of PenL NCR-ESBLs is undoubtedly stabilized by the typical oxyanion hole as well studied in class A &#x03B2;-lactamases.</p>
<p>In addition to Arg275, Arg104 also contributed to the oxyanion hole (<xref ref-type="fig" rid="F3">Figures 3</xref>, <xref ref-type="fig" rid="F4">4</xref>). For example, Arg104 present in the lid of PenL-Cys69Tyr, protruding into the ligand-binding cleft of the enzyme together with Asn132 and W5, increased the positive charge of the oxyanion hole for further stabilization of the Michaelis complex (<xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S7</xref>). Interestingly, the mode of interaction of Arg104 in PenL-Cys69Tyr resembled the oxyanion holes in multistep enzymes, such as thiolase (<xref ref-type="bibr" rid="B26">Kursula et al., 2002</xref>), which contain a &#x201C;second oxyanion hole&#x201D; with basic amino acids and water molecules. PenL-Asn136Asp showed relatively less perturbation of &#x03B2;3-&#x03B2;4, &#x03B2;5-&#x03B1;8, and penetration of Arg104; however, it may have transiently altered the electric potential around the oxyanion hole according to the protein dynamism theory (<xref ref-type="bibr" rid="B50">Tokuriki and Tawfik, 2009</xref>; <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S8</xref>). Indeed, MD simulations showed that Arg104 in PenL-Asn136Asp fluctuated similarly as in the PenL-Cys69Tyr (<xref ref-type="fig" rid="F5">Figure 5</xref>, <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S8</xref>, and <xref ref-type="supplementary-material" rid="VS4">Supplementary Movie S4</xref>), where the flexible movement of Arg104 could momentarily modulate the electrostatic potential in the potential second oxyanion hole around substrate-binding cleft.</p>
<p>To the best of our knowledge, however, this potential second oxyanion hole has yet to be identified in ESBL catalysis, despite its possible existence in other ESBLs (<xref ref-type="bibr" rid="B47">Shimamura et al., 2002</xref>; <xref ref-type="bibr" rid="B11">Chen et al., 2005</xref>). The existence of the potential second oxyanion hole in the ESBLs may be attributed to their kinetic behaviors (<xref ref-type="bibr" rid="B30">Merilainen et al., 2009</xref>), as well as increased affinity. In other words, the increased affinity of PenL-Cys69Tyr for CAZ may facilitate the acylation step but simultaneously attenuate the deacylation process due to the formation of a stable acyl-enzyme complex, in which Arg104 on the flexible loop could be discharged from the interaction with Asn132 and W6 and subsequently could disrupt the potential &#x201C;second oxyanion hole&#x201D; before releasing a product (<xref ref-type="fig" rid="F3">Figure 3</xref> and <xref ref-type="supplementary-material" rid="TS1">Supplementary Figure S6</xref>). The precise hydrolytic mechanism of CAZ mediated by NCR-ESBLs, however, needs to be further investigated.</p>
<p>In summary, we have described the structural mechanism underlying the hydrolysis of third-generation cephalosporins by novel NCR-ESBLs. Although the mutations were unconventional in that they occurred outside of the catalytic region for hydrolysis and substrate binding, the class A NCR-ESBLs exhibited altered substrate specificity and carried an expanded active site similar to the canonical class A ESBLs. We believe that the novel substrate-spectrum expansion mechanism of the class A &#x03B2;-lactamases described in this study will significantly enhance the current knowledge of the evolutionary trends of ESBLs against new antibiotics. Furthermore, from a practical perspective, such information will be crucial for developing novel and useful inhibitors or antibiotics targeting various class A ESBLs, including emerging NCR-ESBLs.</p>
</sec>
<sec id="S5">
<title>Data Availability Statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="supplementary-material" rid="TS1">Supplementary Material</xref>.</p>
</sec>
<sec id="S6">
<title>Author Contributions</title>
<p>TC and HY performed the experiments and generated the data for this study with an equal contribution. ID, SG, and JC helped with kinetics, CD, molecular dynamics analysis, generating figures, and crystallization. KHL and SR helped design and validation of molecular dynamics results with critical comments. HSK and SHL developed the ideas, designed the experiments, analyzed the data, and prepared the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported partly by the National Research Foundation of Korea (NRF-2016R1D1A1B03932717 and 2019R1F1A1049035 to SHL and NRF-2018R1A2B2006456 to HSK) and Korea Brain Research Institute basic research program funded by the Ministry of Science and ICT (20-BR-03-02 to KHL).</p>
</fn>
</fn-group>
<ack>
<p>We thank the beamline (PLS-5C, 7A, and 11C) at the Pohang Light Source for technical support during data collection. We also thank Dr. Yong Ho Kim at Sungkyunkwan University and Kwangho Nam at the University of Texas at Arlington for their technical assistance with CD spectra and comments for Molecular dynamics experiments and analyses, respectively.</p>
</ack>
<sec id="S9" sec-type="supplementary material"><title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2020.598998/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmolb.2020.598998/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.DOCX" id="TS1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Video_1.MP4" id="VS1" mimetype="video/mp4" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Video_2.MP4" id="VS2" mimetype="video/mp4" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Video_3.MP4" id="VS3" mimetype="video/mp4" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Video_4.MP4" id="VS4" mimetype="video/mp4" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abergel</surname> <given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Molecular replacement: tricks and treats.</article-title> <source><italic>Acta Crystallogr. D Biol. Crystallogr.</italic></source> <volume>69(Pt 11)</volume> <fpage>2167</fpage>&#x2013;<lpage>2173</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444913015291</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname> <given-names>M. J.</given-names></name> <name><surname>Gready</surname> <given-names>J. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Optimization of parameters for molecular dynamics simulation using smooth particle&#x2212;mesh Ewald in GROMACS 4.5.</article-title> <source><italic>J. Comput. Chem.</italic></source> <volume>32</volume> <fpage>2031</fpage>&#x2013;<lpage>2040</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21773</pub-id> <pub-id pub-id-type="pmid">21469158</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Afonine</surname> <given-names>P. V.</given-names></name> <name><surname>Grosse-Kunstleve</surname> <given-names>R. W.</given-names></name> <name><surname>Echols</surname> <given-names>N.</given-names></name> <name><surname>Headd</surname> <given-names>J. J.</given-names></name> <name><surname>Moriarty</surname> <given-names>N. W.</given-names></name> <name><surname>Mustyakimov</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Towards automated crystallographic structure refinement with phenix.refine.</article-title> <source><italic>Acta Crystallogr. D Biol. Crystallogr.</italic></source> <volume>68(Pt 4)</volume> <fpage>352</fpage>&#x2013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444912001308</pub-id> <pub-id pub-id-type="pmid">22505256</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname> <given-names>S.</given-names></name> <name><surname>Pieper</surname> <given-names>U.</given-names></name> <name><surname>Kapadia</surname> <given-names>G.</given-names></name> <name><surname>Pannell</surname> <given-names>L. K.</given-names></name> <name><surname>Herzberg</surname> <given-names>O.</given-names></name></person-group> (<year>1998</year>). <article-title>Role of the &#x00BF;-loop in the activity, substrate specificity, and structure of class A &#x03B2;-lactamase.</article-title> <source><italic>Biochemistry</italic></source> <volume>37</volume> <fpage>3286</fpage>&#x2013;<lpage>3296</lpage>.</citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname> <given-names>S.</given-names></name> <name><surname>Shigematsu</surname> <given-names>N.</given-names></name> <name><surname>Pannell</surname> <given-names>L. K.</given-names></name> <name><surname>Ruvinov</surname> <given-names>S.</given-names></name> <name><surname>Orban</surname> <given-names>J.</given-names></name> <name><surname>Schwarz</surname> <given-names>F.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>Probing the non-proline Cis peptide bond in &#x03B2;-Lactamase from <italic>Staphylococcus aureus</italic> PC1 by the Replacement Asn136 &#x2192; Ala.</article-title> <source><italic>Biochemistry</italic></source> <volume>36</volume> <fpage>10857</fpage>&#x2013;<lpage>10866</lpage>. <pub-id pub-id-type="doi">10.1021/bi970352r</pub-id> <pub-id pub-id-type="pmid">9283075</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname> <given-names>J. M.</given-names></name> <name><surname>Tymoczko</surname> <given-names>J. L.</given-names></name> <name><surname>Stryer</surname> <given-names>L.</given-names></name></person-group> (<year>2012</year>). <source><italic>Biochemistry.</italic></source> <publisher-loc>Kate Ahr Parker</publisher-loc>: <publisher-name>W. H. Freeman and Company</publisher-name>.</citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bethel</surname> <given-names>C. R.</given-names></name> <name><surname>Hujer</surname> <given-names>A. M.</given-names></name> <name><surname>Hujer</surname> <given-names>K. M.</given-names></name> <name><surname>Thomson</surname> <given-names>J. M.</given-names></name> <name><surname>Ruszczycky</surname> <given-names>M. W.</given-names></name> <name><surname>Anderson</surname> <given-names>V. E.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Role of Asp104 in the SHV -Lactamase.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>50</volume> <fpage>4124</fpage>&#x2013;<lpage>4131</lpage>. <pub-id pub-id-type="doi">10.1128/aac.00848-06</pub-id> <pub-id pub-id-type="pmid">16982784</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>N. G.</given-names></name> <name><surname>Shanker</surname> <given-names>S.</given-names></name> <name><surname>Prasad</surname> <given-names>B. V.</given-names></name> <name><surname>Palzkill</surname> <given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>Structural and biochemical evidence that a TEM-1 beta-lactamase N170G active site mutant acts via substrate-assisted catalysis.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>284</volume> <fpage>33703</fpage>&#x2013;<lpage>33712</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.053819</pub-id> <pub-id pub-id-type="pmid">19812041</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Celenza</surname> <given-names>G.</given-names></name> <name><surname>Luzi</surname> <given-names>C.</given-names></name> <name><surname>Aschi</surname> <given-names>M.</given-names></name> <name><surname>Segatore</surname> <given-names>B.</given-names></name> <name><surname>Setacci</surname> <given-names>D.</given-names></name> <name><surname>Pellegrini</surname> <given-names>C.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Natural D240G Toho-1 mutant conferring resistance to ceftazidime: biochemical characterization of CTX-M-43.</article-title> <source><italic>J. Antimicrob. Chemother.</italic></source> <volume>62</volume> <fpage>991</fpage>&#x2013;<lpage>997</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkn339</pub-id> <pub-id pub-id-type="pmid">18755695</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaibi</surname> <given-names>E. B.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name> <name><surname>Farzaneh</surname> <given-names>S.</given-names></name> <name><surname>Barthelemy</surname> <given-names>M.</given-names></name> <name><surname>Sirot</surname> <given-names>D.</given-names></name> <name><surname>Labia</surname> <given-names>R.</given-names></name></person-group> (<year>1998</year>). <article-title>Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling.</article-title> <source><italic>Biochim. Biophys. Acta</italic></source> <volume>1382</volume> <fpage>38</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/s0167-4838(97)00127-1</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y.</given-names></name> <name><surname>Shoichet</surname> <given-names>B.</given-names></name> <name><surname>Bonnet</surname> <given-names>R.</given-names></name></person-group> (<year>2005</year>). <article-title>Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases.</article-title> <source><italic>J. Am. Chem. Soc.</italic></source> <volume>127</volume> <fpage>5423</fpage>&#x2013;<lpage>5434</lpage>. <pub-id pub-id-type="doi">10.1021/ja042850a</pub-id> <pub-id pub-id-type="pmid">15826180</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dance</surname> <given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Treatment and prophylaxis of melioidosis.</article-title> <source><italic>Int. J. Antimicrob. Agents</italic></source> <volume>43</volume> <fpage>310</fpage>&#x2013;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.01.005</pub-id> <pub-id pub-id-type="pmid">24613038</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname> <given-names>R.</given-names></name> <name><surname>Yi</surname> <given-names>H.</given-names></name> <name><surname>Cho</surname> <given-names>K.-H.</given-names></name> <name><surname>Cho</surname> <given-names>Y. S.</given-names></name> <name><surname>Kim</surname> <given-names>K.</given-names></name> <name><surname>Nierman</surname> <given-names>W. C.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Twelve positions in a &#x03B2;-lactamase that can expand its substrate spectrum with a single amino acid substitution.</article-title> <source><italic>PLoS One</italic></source> <volume>7</volume>:<issue>e37585</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0037585</pub-id> <pub-id pub-id-type="pmid">22629423</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doucet</surname> <given-names>N.</given-names></name> <name><surname>De Wals</surname> <given-names>P.-Y.</given-names></name> <name><surname>Pelletier</surname> <given-names>J. N.</given-names></name></person-group> (<year>2004</year>). <article-title>Site-saturation mutagenesis of Tyr-105 reveals its importance in substrate stabilization and discrimination in TEM-1 &#x03B2;-Lactamase.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>279</volume> <fpage>46295</fpage>&#x2013;<lpage>46303</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M407606200</pub-id> <pub-id pub-id-type="pmid">15326193</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drawz</surname> <given-names>S. M.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Three decades of beta-lactamase inhibitors.</article-title> <source><italic>Clin. Microbiol. Rev.</italic></source> <volume>23</volume> <fpage>160</fpage>&#x2013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00037-09</pub-id> <pub-id pub-id-type="pmid">20065329</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du Bois</surname> <given-names>S. K.</given-names></name> <name><surname>Marriott</surname> <given-names>M. S.</given-names></name> <name><surname>Amyes</surname> <given-names>S. G.</given-names></name></person-group> (<year>1995</year>). <article-title>TEM- and SHV-derived extended-spectrum beta-lactamases: relationship between selection, structure and function.</article-title> <source><italic>J. Antimicrob. Chemother.</italic></source> <volume>35</volume> <fpage>7</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1093/jac/35.1.7</pub-id> <pub-id pub-id-type="pmid">7768784</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Echols</surname> <given-names>N.</given-names></name> <name><surname>Moriarty</surname> <given-names>N. W.</given-names></name> <name><surname>Klei</surname> <given-names>H. E.</given-names></name> <name><surname>Afonine</surname> <given-names>P. V.</given-names></name> <name><surname>Bunkoczi</surname> <given-names>G.</given-names></name> <name><surname>Headd</surname> <given-names>J. J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Automating crystallographic structure solution and refinement of protein-ligand complexes.</article-title> <source><italic>Acta Crystallogr. D Biol. Crystallogr.</italic></source> <volume>70(Pt 1)</volume> <fpage>144</fpage>&#x2013;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1107/S139900471302748X</pub-id> <pub-id pub-id-type="pmid">24419387</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>P.</given-names></name> <name><surname>Cowtan</surname> <given-names>K.</given-names></name></person-group> (<year>2004</year>). <article-title>Coot: model-building tools for molecular graphics.</article-title> <source><italic>Acta Crystallogr. D Biol. Crystallogr.</italic></source> <volume>60(Pt 12)</volume> <fpage>2126</fpage>&#x2013;<lpage>2132</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id> <pub-id pub-id-type="pmid">15572765</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giakkoupi</surname> <given-names>P.</given-names></name> <name><surname>Hujer</surname> <given-names>A. M.</given-names></name> <name><surname>Miriagou</surname> <given-names>V.</given-names></name> <name><surname>Tzelepi</surname> <given-names>E.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Tzouvelekis</surname> <given-names>L. S.</given-names></name></person-group> (<year>2001</year>). <article-title>Substitution of Thr for Ala-237 in TEM-17, TEM-12 and TEM-26: alterations in &#x03B2;-lactam resistance conferred on <italic>Escherichia coli</italic>.</article-title> <source><italic>FEMS Microbiol. Lett.</italic></source> <volume>201</volume> <fpage>37</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/s0378-1097(01)00239-7</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giakkoupi</surname> <given-names>P.</given-names></name> <name><surname>Miriagou</surname> <given-names>V.</given-names></name> <name><surname>Gazouli</surname> <given-names>M.</given-names></name> <name><surname>Tzelepi</surname> <given-names>E.</given-names></name> <name><surname>Legakis</surname> <given-names>N. J.</given-names></name> <name><surname>Tzouvelekis</surname> <given-names>L. S.</given-names></name></person-group> (<year>1998</year>). <article-title>Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position 69.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>42</volume> <fpage>1281</fpage>&#x2013;<lpage>1283</lpage>. <pub-id pub-id-type="doi">10.1128/aac.42.5.1281</pub-id> <pub-id pub-id-type="pmid">9593168</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gniadkowski</surname> <given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms.</article-title> <source><italic>Clin. Microbiol. Infect.</italic></source> <volume>7</volume> <fpage>597</fpage>&#x2013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1046/j.1198-743x.2001.00330.x</pub-id> <pub-id pub-id-type="pmid">11737084</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guillaume</surname> <given-names>G.</given-names></name> <name><surname>Vanhove</surname> <given-names>M.</given-names></name> <name><surname>Lamotte-Brasseur</surname> <given-names>J.</given-names></name> <name><surname>Ledent</surname> <given-names>P.</given-names></name> <name><surname>Jamin</surname> <given-names>M.</given-names></name> <name><surname>Joris</surname> <given-names>B.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>Site-directed mutagenesis of glutamate 166 in Two b-Lactamases.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>272</volume> <fpage>5438</fpage>&#x2013;<lpage>5444</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.272.9.5438</pub-id> <pub-id pub-id-type="pmid">9038144</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helfand</surname> <given-names>M. S.</given-names></name> <name><surname>Hujer</surname> <given-names>A. M.</given-names></name> <name><surname>S&#x00F6;nnichsen</surname> <given-names>F. D.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV &#x03B2;-Lactamase.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>277</volume> <fpage>47719</fpage>&#x2013;<lpage>47723</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M207271200</pub-id> <pub-id pub-id-type="pmid">12354765</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huletsky</surname> <given-names>A.</given-names></name> <name><surname>Knox</surname> <given-names>J. R.</given-names></name> <name><surname>Levesque</surname> <given-names>R. C.</given-names></name></person-group> (<year>1993</year>). <article-title>Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type beta-lactamases probed by site-directed mutagenesis and three-dimensional modeling.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>268</volume> <fpage>3690</fpage>&#x2013;<lpage>3697</lpage>.</citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname> <given-names>J. D.</given-names></name></person-group> (<year>2007</year>). <article-title>Matplotlib: a 2D graphics environment.</article-title> <source><italic>Comput. Sci. Eng.</italic></source> <volume>9</volume> <fpage>90</fpage>&#x2013;<lpage>95</lpage>.</citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kursula</surname> <given-names>P.</given-names></name> <name><surname>Ojala</surname> <given-names>J.</given-names></name> <name><surname>Lambeir</surname> <given-names>A. M.</given-names></name> <name><surname>Wierenga</surname> <given-names>R. K.</given-names></name></person-group> (<year>2002</year>). <article-title>The catalytic cycle of biosynthetic thiolase: a conformational journey of an acetyl group through four binding modes and two oxyanion holes.</article-title> <source><italic>Biochemistry</italic></source> <volume>41</volume> <fpage>15543</fpage>&#x2013;<lpage>15556</lpage>. <pub-id pub-id-type="doi">10.1021/bi0266232</pub-id> <pub-id pub-id-type="pmid">12501183</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamotte-Brasseur</surname> <given-names>J.</given-names></name> <name><surname>Dive</surname> <given-names>G.</given-names></name> <name><surname>Dideberg</surname> <given-names>O.</given-names></name> <name><surname>Charlier</surname> <given-names>P.</given-names></name> <name><surname>Frere</surname> <given-names>J. M.</given-names></name> <name><surname>Ghuysen</surname> <given-names>J. M.</given-names></name></person-group> (<year>1991</year>). <article-title>Mechanism of acyl transfer by the class A serine beta-lactamase of <italic>Streptomyces albus</italic> G.</article-title> <source><italic>Biochem. J.</italic></source> <volume>279(Pt 1)</volume> <fpage>213</fpage>&#x2013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1042/bj2790213</pub-id> <pub-id pub-id-type="pmid">1930139</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lemkul</surname> <given-names>J. A.</given-names></name> <name><surname>Roux</surname> <given-names>B.</given-names></name> <name><surname>van der Spoel</surname> <given-names>D.</given-names></name> <name><surname>MacKerell</surname> <given-names>A. D.</given-names> <suffix>Jr.</suffix></name></person-group> (<year>2015</year>). <article-title>Implementation of extended Lagrangian dynamics in GROMACS for polarizable simulations using the classical Drude oscillator model.</article-title> <source><italic>J. Comput. Chem.</italic></source> <volume>36</volume> <fpage>1473</fpage>&#x2013;<lpage>1479</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.23937</pub-id> <pub-id pub-id-type="pmid">25962472</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levitt</surname> <given-names>P. S.</given-names></name> <name><surname>Papp-Wallace</surname> <given-names>K. M.</given-names></name> <name><surname>Taracila</surname> <given-names>M. A.</given-names></name> <name><surname>Hujer</surname> <given-names>A. M.</given-names></name> <name><surname>Winkler</surname> <given-names>M. L.</given-names></name> <name><surname>Smith</surname> <given-names>K. M.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Exploring the role of a conserved class a residue in the &#x03A9;-Loop of KPC-2 &#x03B2;-Lactamase.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>287</volume> <fpage>31783</fpage>&#x2013;<lpage>31793</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.348540</pub-id> <pub-id pub-id-type="pmid">22843686</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merilainen</surname> <given-names>G.</given-names></name> <name><surname>Poikela</surname> <given-names>V.</given-names></name> <name><surname>Kursula</surname> <given-names>P.</given-names></name> <name><surname>Wierenga</surname> <given-names>R. K.</given-names></name></person-group> (<year>2009</year>). <article-title>The thiolase reaction mechanism: the importance of Asn316 and His348 for stabilizing the enolate intermediate of the Claisen condensation.</article-title> <source><italic>Biochemistry</italic></source> <volume>48</volume> <fpage>11011</fpage>&#x2013;<lpage>11025</lpage>. <pub-id pub-id-type="doi">10.1021/bi901069h</pub-id> <pub-id pub-id-type="pmid">19842716</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meroueh</surname> <given-names>S. O.</given-names></name> <name><surname>Fisher</surname> <given-names>J. F.</given-names></name> <name><surname>Schlegel</surname> <given-names>H. B.</given-names></name> <name><surname>Mobashery</surname> <given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Ab Initio QM/MM study of class A b-Lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70.</article-title> <source><italic>J. Am. Chem. Soc.</italic></source> <volume>127</volume> <fpage>15397</fpage>&#x2013;<lpage>15407</lpage>. <pub-id pub-id-type="doi">10.1021/ja051592u</pub-id> <pub-id pub-id-type="pmid">16262403</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meroueh</surname> <given-names>S. O.</given-names></name> <name><surname>Roblin</surname> <given-names>P.</given-names></name> <name><surname>Golemi</surname> <given-names>D.</given-names></name> <name><surname>Maveyraud</surname> <given-names>L.</given-names></name> <name><surname>Vakulenko</surname> <given-names>S. B.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM b-lactamase from <italic>Escherichia coli</italic>.</article-title> <source><italic>J. Am. Chem. Soc.</italic></source> <volume>124</volume> <fpage>9422</fpage>&#x2013;<lpage>9430</lpage>. <pub-id pub-id-type="doi">10.1021/ja026547q</pub-id> <pub-id pub-id-type="pmid">12167037</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murshudov</surname> <given-names>G. N.</given-names></name> <name><surname>Vagin</surname> <given-names>A. A.</given-names></name> <name><surname>Dodson</surname> <given-names>E. J.</given-names></name></person-group> (<year>1997</year>). <article-title>Refinement of macromolecular structures by the maximum-likelihood method.</article-title> <source><italic>Acta Crystallogr. D Biol. Crystallogr.</italic></source> <volume>53(Pt 3)</volume> <fpage>240</fpage>&#x2013;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444996012255</pub-id> <pub-id pub-id-type="pmid">15299926</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliphant</surname> <given-names>T. E.</given-names></name></person-group> (<year>2007</year>). <article-title>Python for scientific computing.</article-title> <source><italic>Comput. Sci. Eng.</italic></source> <volume>9</volume> <fpage>10</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1109/Mcse.2007.58</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orencia</surname> <given-names>M. C.</given-names></name> <name><surname>Yoon</surname> <given-names>J. S.</given-names></name> <name><surname>Ness</surname> <given-names>J. E.</given-names></name> <name><surname>Stemmer</surname> <given-names>W. P.</given-names></name> <name><surname>Stevens</surname> <given-names>R. C.</given-names></name></person-group> (<year>2001</year>). <article-title>Predicting the emergence of antibiotic resistance by directed evolution and structural analysis.</article-title> <source><italic>Nat. Struct. Biol.</italic></source> <volume>8</volume> <fpage>238</fpage>&#x2013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1038/84981</pub-id> <pub-id pub-id-type="pmid">11224569</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Page</surname> <given-names>M. G. P.</given-names></name></person-group> (<year>2008</year>). <article-title>Extended-spectrum &#x03B2;-lactamases: structure and kinetic mechanism.</article-title> <source><italic>Clin. Microbiol. Infect.</italic></source> <volume>14</volume> <fpage>63</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2007.01863.x</pub-id> <pub-id pub-id-type="pmid">18154529</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palzkill</surname> <given-names>T.</given-names></name></person-group> (<year>2018</year>). <article-title>Structural and mechanistic basis for extended-spectrum drug-resistance mutations in altering the specificity of TEM, CTX-M, and KPC beta-lactamases.</article-title> <source><italic>Front. Mol. Biosci.</italic></source> <volume>5</volume>:<issue>16</issue>. <pub-id pub-id-type="doi">10.3389/fmolb.2018.00016</pub-id> <pub-id pub-id-type="pmid">29527530</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papp-Wallace</surname> <given-names>K. M.</given-names></name> <name><surname>Taracila</surname> <given-names>M.</given-names></name> <name><surname>Hornick</surname> <given-names>J. M.</given-names></name> <name><surname>Hujer</surname> <given-names>A. M.</given-names></name> <name><surname>Hujer</surname> <given-names>K. M.</given-names></name> <name><surname>Distler</surname> <given-names>A. M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>54</volume> <fpage>2867</fpage>&#x2013;<lpage>2877</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00197-10</pub-id> <pub-id pub-id-type="pmid">20421396</pub-id></citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papp-Wallace</surname> <given-names>K. M.</given-names></name> <name><surname>Taracila</surname> <given-names>M. A.</given-names></name> <name><surname>Gatta</surname> <given-names>J. A.</given-names></name> <name><surname>Ohuchi</surname> <given-names>N.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Nukaga</surname> <given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Insights into beta-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>288</volume> <fpage>19090</fpage>&#x2013;<lpage>19102</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.458315</pub-id> <pub-id pub-id-type="pmid">23658015</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papp-Wallace</surname> <given-names>K. M.</given-names></name> <name><surname>Taracila</surname> <given-names>M. A.</given-names></name> <name><surname>Smith</surname> <given-names>K. M.</given-names></name> <name><surname>Xu</surname> <given-names>Y.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>56</volume> <fpage>4428</fpage>&#x2013;<lpage>4438</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.05769-11</pub-id> <pub-id pub-id-type="pmid">22687511</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>M. P.</given-names></name> <name><surname>Hu</surname> <given-names>L.</given-names></name> <name><surname>Stojanoski</surname> <given-names>V.</given-names></name> <name><surname>Sankaran</surname> <given-names>B.</given-names></name> <name><surname>Prasad</surname> <given-names>B. V. V.</given-names></name> <name><surname>Palzkill</surname> <given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>The drug-resistant variant P167S expands the substrate profile of CTX-M beta-Lactamases for Oxyimino-Cephalosporin Antibiotics by Enlarging the Active Site upon Acylation.</article-title> <source><italic>Biochemistry</italic></source> <volume>56</volume> <fpage>3443</fpage>&#x2013;<lpage>3453</lpage>. <pub-id pub-id-type="doi">10.1021/acs.biochem.7b00176</pub-id> <pub-id pub-id-type="pmid">28613873</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname> <given-names>F.</given-names></name> <name><surname>Endimiani</surname> <given-names>A.</given-names></name> <name><surname>Hujer</surname> <given-names>K. M.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name></person-group> (<year>2007</year>). <article-title>The continuing challenge of ESBLs.</article-title> <source><italic>Curr. Opin. Pharmacol.</italic></source> <volume>7</volume> <fpage>459</fpage>&#x2013;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2007.08.003</pub-id> <pub-id pub-id-type="pmid">17875405</pub-id></citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname> <given-names>A.</given-names></name> <name><surname>Maveyraud</surname> <given-names>L.</given-names></name> <name><surname>Lenfant</surname> <given-names>F.</given-names></name> <name><surname>Samama</surname> <given-names>J. P.</given-names></name> <name><surname>Labia</surname> <given-names>R.</given-names></name> <name><surname>Masson</surname> <given-names>J. M.</given-names></name></person-group> (<year>1995</year>). <article-title>Multiple substitutions at position 104 of b-lactamase TEM-1: assessing the role of this residue in substrate specificity.</article-title> <source><italic>Biochem. J.</italic></source> <volume>305</volume> <fpage>33</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1042/bj3050033</pub-id> <pub-id pub-id-type="pmid">7826350</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname> <given-names>M. C.</given-names></name> <name><surname>Horta</surname> <given-names>V. A. C.</given-names></name> <name><surname>Horta</surname> <given-names>B. A. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Molecular dynamics simulations of PAMAM and PPI dendrimers using the GROMOS-Compatible 2016H66 Force Field.</article-title> <source><italic>J. Chem. Inform. Model.</italic></source> <volume>59</volume> <fpage>1444</fpage>&#x2013;<lpage>1457</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00911</pub-id> <pub-id pub-id-type="pmid">30875214</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruggiero</surname> <given-names>M.</given-names></name> <name><surname>Curto</surname> <given-names>L.</given-names></name> <name><surname>Brunetti</surname> <given-names>F.</given-names></name> <name><surname>Sauvage</surname> <given-names>E.</given-names></name> <name><surname>Galleni</surname> <given-names>M.</given-names></name> <name><surname>Power</surname> <given-names>P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Impact of Mutations at Arg220 and Thr237 in PER-2 &#x03B2;-lactamase on conformation, activity, and susceptibility to inhibitors.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>61</volume> <issue>e02193-16</issue>. <pub-id pub-id-type="doi">10.1128/aac.02193-16</pub-id> <pub-id pub-id-type="pmid">28320728</pub-id></citation></ref>
<ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sam</surname> <given-names>I. C.</given-names></name> <name><surname>See</surname> <given-names>K. H.</given-names></name> <name><surname>Puthucheary</surname> <given-names>S. D.</given-names></name></person-group> (<year>2009</year>). <article-title>Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of <italic>Burkholderia pseudomallei</italic>.</article-title> <source><italic>J. Clin. Microbiol.</italic></source> <volume>47</volume> <fpage>1556</fpage>&#x2013;<lpage>1558</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.01657-08</pub-id></citation></ref>
<ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimamura</surname> <given-names>T.</given-names></name> <name><surname>Ibuka</surname> <given-names>A.</given-names></name> <name><surname>Fushinobu</surname> <given-names>S.</given-names></name> <name><surname>Wakagi</surname> <given-names>T.</given-names></name> <name><surname>Ishiguro</surname> <given-names>M.</given-names></name> <name><surname>Ishii</surname> <given-names>Y.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>277</volume> <fpage>46601</fpage>&#x2013;<lpage>46608</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M207884200</pub-id> <pub-id pub-id-type="pmid">12221102</pub-id></citation></ref>
<ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimizu-Ibuka</surname> <given-names>A.</given-names></name> <name><surname>Oishi</surname> <given-names>M.</given-names></name> <name><surname>Yamada</surname> <given-names>S.</given-names></name> <name><surname>Ishii</surname> <given-names>Y.</given-names></name> <name><surname>Mura</surname> <given-names>K.</given-names></name> <name><surname>Sakai</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum &#x03B2;-Lactamase Toho-1.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>55</volume> <fpage>284</fpage>&#x2013;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1128/aac.00098-10</pub-id> <pub-id pub-id-type="pmid">21078949</pub-id></citation></ref>
<ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sirot</surname> <given-names>D.</given-names></name> <name><surname>Recule</surname> <given-names>C.</given-names></name> <name><surname>Chaibi</surname> <given-names>E. B.</given-names></name> <name><surname>Bret</surname> <given-names>L.</given-names></name> <name><surname>Croize</surname> <given-names>J.</given-names></name> <name><surname>Chanal-Claris</surname> <given-names>C.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>A complex mutant of TEM-1 b-Lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15 produced by an <italic>Escherichia coli</italic> clinical isolate.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>41</volume> <fpage>1322</fpage>&#x2013;<lpage>1325</lpage>. <pub-id pub-id-type="doi">10.1128/aac.41.6.1322</pub-id> <pub-id pub-id-type="pmid">9174192</pub-id></citation></ref>
<ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokuriki</surname> <given-names>N.</given-names></name> <name><surname>Tawfik</surname> <given-names>D. S.</given-names></name></person-group> (<year>2009</year>). <article-title>Protein dynamism and evolvability.</article-title> <source><italic>Science</italic></source> <volume>324</volume> <fpage>203</fpage>&#x2013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1126/science.1169375</pub-id> <pub-id pub-id-type="pmid">19359577</pub-id></citation></ref>
<ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Totir</surname> <given-names>M. A.</given-names></name> <name><surname>Padayatti</surname> <given-names>P. S.</given-names></name> <name><surname>Helfand</surname> <given-names>M. S.</given-names></name> <name><surname>Carey</surname> <given-names>M. P.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Carey</surname> <given-names>P. R.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.</article-title> <source><italic>Biochemistry</italic></source> <volume>45</volume> <fpage>11895</fpage>&#x2013;<lpage>11904</lpage>. <pub-id pub-id-type="doi">10.1021/bi060990m</pub-id> <pub-id pub-id-type="pmid">17002290</pub-id></citation></ref>
<ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Minasov</surname> <given-names>G.</given-names></name> <name><surname>Shoichet</surname> <given-names>B. K.</given-names></name></person-group> (<year>2002a</year>). <article-title>Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs.</article-title> <source><italic>J. Mol. Biol.</italic></source> <volume>320</volume> <fpage>85</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-2836(02)00400-X</pub-id></citation></ref>
<ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Minasov</surname> <given-names>G.</given-names></name> <name><surname>Shoichet</surname> <given-names>B. K.</given-names></name></person-group> (<year>2002b</year>). <article-title>The structural bases of antibiotic resistance in the clinically derived mutant &#x03B2;-Lactamases TEM-30, TEM-32, and TEM-34.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>277</volume> <fpage>32149</fpage>&#x2013;<lpage>32156</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M204212200</pub-id> <pub-id pub-id-type="pmid">12058046</pub-id></citation></ref>
<ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname> <given-names>H.</given-names></name> <name><surname>Choi</surname> <given-names>J. M.</given-names></name> <name><surname>Hwang</surname> <given-names>J.</given-names></name> <name><surname>Prati</surname> <given-names>F.</given-names></name> <name><surname>Cao</surname> <given-names>T.-P.</given-names></name> <name><surname>Lee</surname> <given-names>S. H.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>High adaptability of the omega loop underlies the substrate-spectrum-extension evolution of a class A &#x03B2;-lactamase, PenL.</article-title> <source><italic>Sci. Rep.</italic></source> <volume>6</volume>:<issue>36527</issue>. <pub-id pub-id-type="doi">10.1038/srep36527</pub-id> <pub-id pub-id-type="pmid">27827433</pub-id></citation></ref>
</ref-list>
<fn-group>
<fn id="footnote1">
<label>1</label>
<p><ext-link ext-link-type="uri" xlink:href="https://www.lahey.org/Studies/">https://www.lahey.org/Studies/</ext-link></p></fn>
</fn-group>
</back>
</article>